emd1214063 has been researched along with sotorasib* in 1 studies
1 other study(ies) available for emd1214063 and sotorasib
| Article | Year |
|---|---|
Approved spectrofluorimetric strategies for assurance of three modern antineoplastic drugs: tepotinib, sotorasib, and darolutamide in their dose forms and biological liquids utilizing mercurochrome.
An approved, straightforward, fast, and delicate spectrofluorimetric strategy was developed for the estimation of tepotinib (TEPO), sotorasib (SOTO), and darolutamide (DARO) as new antineoplastic drugs. The spectrofluorimetric strategy was based on quantitative fluorescence quenching of MER at 538 nm after being excited at 350 nm by the addition of the cited drugs in the presence of acetate buffer (pH 3.5). The degree of fluorescence quenching was directly proportional to the concentrations of the cited drugs within the concentration range of 0.5-10.0, 0.2-10, and 0.4-10.0 μg ml Topics: Antineoplastic Agents; Humans; Merbromin; Piperazines; Piperidines; Pyrazoles; Pyridazines; Pyridines; Pyrimidines; Spectrometry, Fluorescence | 2022 |